CMS Open Payments · Program Year 2024
Valley Contax, Inc.
Valley Contax, Inc. reported $90,402.68 across General Payments, Research, and Ownership to 107 physicians and teaching hospitals across 107 transactions.
- $90.4K Below-median payer
- All-tracks total
- 107 Below-median volume
- Transactions
- 107 Below-median reach
- Recipients
- +$7.3K
- General Payments vs PY2023
Valley Contax, Inc. reported $90,402.68 across all CMS Open Payments tracks (General + Research + Ownership) to 107 physicians and teaching hospitals in Program Year 2024 - ranking #1209 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $90,402.68, averaging $844.88 per recipient.
Valley Contax, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
11/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer valley-contax-inc Valley Contax, Inc.
$90.4K · #1209/1,925 · 0.0% industry · PY2024
- TOT $90.4K
- RANK #1209
- SHARE 0.0%
- TXN 107
- RCP 107
- CAT 4
- GEN $90.4K
- ΔGEN +$7.3K
- TOP1 16.1%
- PY 2024
Volume peers
Nearest volume peer: Pbg Puerto Rico LLC ($90.6K)
Valley Contax, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Valley Contax, Inc.'s CMS-reported General Payments increased by $7.3K (+8.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VALLEY CONTAX, INC.PY2023: VALLEY CONTAX, INC.PY2024: Valley Contax, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $83,098.66
- PY2024
- $90,402.68
What the Data Shows for Valley Contax, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Valley Contax, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
27 transactions worth $33.9K make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 37.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, Valley Contax, Inc.'s largest category was "Consulting Fee" at $33.9K - 37.5% of General Payments.
Valley Contax, Inc. reports 4 general-payment categories - the top three are Consulting Fee (37.5%), Travel and Lodging (36.3%), and Food and Beverage (22.2%). The remaining 1 category make up 4.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Valley Contax, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $33.9K | 27 | 37.5% |
| Travel and Lodging | $32.8K | 30 | 36.3% |
| Food and Beverage | $20.0K | 32 | 22.2% |
| Entertainment | $3.6K | 18 | 4.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $42,823.97 (47.4%) of $90,402.68 in this company's General Payments records across 25 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Valley Contax, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Roya Habibi
$14,516.68 across 13 reported transactions
- 2
Josh Lotoczky
$13,097.42 across 13 reported transactions
- 3
Colton Heinrich
$6,739.43 across 13 reported transactions
- 4
Brianna Ryff
$5,416.13 across 9 reported transactions
- 5
Kishan Patel
$3,054.31 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Valley Contax, Inc.'s spend rank (#1209 of 1,925, bottom 37% by spend) and concentration rank (#1,161 of 1,838, bottom 37% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Uswm, LLC : $57.8K total payments, HHI 743
- Tokuyama Dental America Inc. : $79.2K total payments, HHI 733
- Samsung Bioepis Co., Ltd. : $85.2K total payments, HHI 728
- PharmaEssentia USA Corporation : $714.5K total payments, HHI 727
- Exactech, Inc. : $8.1M total payments, HHI 722
- Guerbet LLC : $589.2K total payments, HHI 722
- Valley Contax, Inc. (this company) : $90.4K total payments, HHI 721
- Intera Oncology, Inc : $90.9K total payments, HHI 720
- EMD Serono Research & Development Institute, Inc. : $320.3K total payments, HHI 719
- Brainlab, Inc. : $119.2K total payments, HHI 717
- Central Indiana URS Consumables, LLC : $214.2K total payments, HHI 714
- Guard Medical Inc. : $77.8K total payments, HHI 712
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Valley Contax, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Valley Contax, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Valley Contax, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Change Healthcare Technologies, LLC
Supreme Orthopedic Systems, LLC
Pinnacle, Inc
Thommen Medical USA, LLC
STRATA Skin Sciences, Inc.
Put this to use
Valley Contax, Inc. ranks #1209 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Valley Contax, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.